 NASHVILLE, TN ACCESSWIRE July 22, 2021 EV Biologics Corp., OTC PINK:YECO today announced that it has signed a Letter of Intent LOI with Lonza Cell Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles EVs and particles, as well as other secreted factors derived from selected stemprogenitor cells, such as mesenchymal stromal cells MSCs. Lonza is one of the leading global manufacturers serving the biotechnology and pharmaceutical industries. 